



Disclosures

Personal Commercial (9)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|------------------------------|---|--------------------------|------------------------------------|
| <i>Self</i> | | | |
| Biomarin | Other - Research funding to my institution | Significant (>= \$5,000) | |
| Bristol Meyers Squib | Consultant Fees/Honoraria | Modest (< \$5,000) | |
| Bristol-Myers Squibb Company | Other - Research funding provided to my institution (I am the PI) | Significant (>= \$5,000) | |
| Cytokinetics | Other - Research funding provided to my institution (I am the PI) | Significant (>= \$5,000) | |
| Cytokinetics | Consultant Fees/Honoraria | Modest (< \$5,000) | |
| Lexicon | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Pfizer Inc | Other - Research funding provided to my institution (I am the PI) | Significant (>= \$5,000) | |
| Rocket Pharmaceuticals | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| viz-AI | Consultant Fees/Honoraria | Modest (< \$5,000) | |

Additional Personal Commercial Disclosures for Education Activities (3)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|-----------------|---------------------------|--------------------|------------------------------------|
| <i>Self</i> | | | |
| Medscape | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Radcliffe Group | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| WebMD | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (1)

| Trial Name | Trial Sponsor | Trial Funding Source |
|--|----------------------|----------------------|
| Study of efficacy of sacubitril/valsartan in adults with non-obstructive HCM | Novartis Corporation | |

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 9/20/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 9/20/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 9/20/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.